CEOs, Senior Executives Highlight Expansions at the DCAT Member Company Announcement Forum

CEOs and senior executives from DCAT Member Companies highlighted their companies’ major news at the DCAT Member Company Announcement Forum at DCAT Week. Capital expansions for small-molecule API manufacturing, including HPAPIs, biologics, and fill-finish topped the news.

CEOs and senior executives from DCAT Member Companies highlighted their companies’ major news at the DCAT Member Company Announcement Forum at DCAT Week. Capital expansions for small-molecule API manufacturing, including HPAPIs, biologics, and fill-finish topped the news.

By Patricia Van Arnum, Editorial Director, DCAT, pvanarnum@dcat.org 

CEO and senior executives from DCAT Member Companies highlighted their companies’ major news at the DCAT Member Company Announcement Forum at DCAT Week, the flagship event of the Drug, Chemical & Associated Technologies Association (DCAT) and the premier event for the global bio/pharmaceutical business ecosystem. Companies reported the latest in expansion plans across the bio/pharmaceutical value chain: from drug substances (small-molecules and biologics) to drug products (solid dosage and injectable product forms) and packaging. In all, 20 companies took to the podium to make their announcements. The program kicked off DCAT Week on Monday March 23, 2026. 

Details of each company’s announcement can be found below. 

Recent Feature Articles

DCAT Value Chain Insights Bonus Coverage: From DCAT Week 2026 Member Company News Roundup 

By
What other DCAT Member Companies are making news from DCAT Week? A roundup of the latest developments from suppliers and CDMOs/CMOs of small-molecule active pharmaceutical ingredients and packaging. 

DCAT Week in Review: A Snapshot View of DCAT’s Education Programs

By
The education programs at DCAT Week 2026, held March 23–26, in New York, featured senior executives and thought leaders providing perspectives on key issues impactful to the business of bio/pharma development and manufacturing and the pharma customer–supplier relationship.

Oral Obesity Drug Battle Is On with FDA OK for Lilly’s Orforglipron

By
Lilly is entering the oral obesity drug market by gaining FDA approval for Foundayo (orforglipron), a small-molecule (non-peptide) oral GLP-1 receptor agonist, setting up head-on competition with an oral version of Novo Nordisk’s obesity drug, Wegovy (semaglutide).

What is Top of the Industry’s Sustainability Agenda in 2026?

By
Decarbonizing, standardized reporting of value-chain emissions, and coalescing talent and technology are high on the industry’s sustainability agenda in 2026.